People Who Inject Drugs
In addition, the following individuals of our external expert advisory committee made instrumental contributions to the initial design and content of the document: Billy Pick, USAID; Daniel Wolfe, Open Society Foundations; Dave Burrows, AIDS Projects Management Group; Fabi...enne Hariga, United Nations Office on Drugs and Crime; Mauro Guarinieri, the Global Fund to Fight AIDS, Tuberculosis and Malaria; Richard Needle, Office of the U.S. Global AIDS Coordinator; and Sergey Votyagov, EHRN.
more
Participant Manual September 2012
Surveillance of Populations at High Risk for HIV Transmission
DHS Further Analysis Reports No. 89 - The 2010 Rwanda Demographic and Health Survey shows that 3 percent of Rwandan adults age 15-49 have been infected with HIV. The prevalence was much higher in urban areas, among women, and among adults who had multiple lifetime sexual partners and used a condom a...t last sexual intercourse. The
level of and differences in HIV prevalence in Rwanda in 2010 are very similar to those observed in 2005. Using data from the two recent Rwanda Demographic and Health Surveys, implemented in 2005 and
2010, this study examined changes in key HIV-related knowledge, attitudes, and sexual behavior indicators. Significant changes in selected indicators during 2005 and 2010 were determined by Student ttest with p-values less than 0.05.
more
UNAIDS and the World Health Organization have published this updated guidance on ethical considerations in HIV prevention trials. The new guidance is the result of a year-long process that saw more than 80 experts and members of the public give inputs and is published 21 years after the first editio...n appeared.
more
This summary highlights the experiences, results and actions from
the implementation of the Rapid Assessment Tool for Sexual and
The tool – developed by IPPF, UNFPA, WHO, UNAIDS, GNP+, ICW and Young Positives in
2009 – supports national assessments of the bi-directional linkages
between sexu...al and reproductive health (SRH) and HIV at the policy,
systems and services levels. Each country that has rolled out the
tool has gathered and generated information that will help to
determine priorities and shape national plans and frameworks for
scaling up and intensifying linkages. Country experiences and best
practices will also inform regional and global agendas.
more
Donor government disbursements to combat HIV in low- and middle-income countries totaled US$8 billion in 2018, little changed from the US$8.1 billion total in 2017 and from the levels of a decade ago, finds a new report from the Kaiser Family Foundation (KFF) and the Joint United Nations Programme o...n HIV/AIDS (UNAIDS)
more
BMC Public Health (2021) 21:299 https://doi.org/10.1186/s12889-021-10296-9
PLoS Pathogens | www.plospathogens.org 1
February 2012 | Volume 8 | Issue 2 | e100246
This report explores the extent to which evidence, policy, normative guidance and commitments on HIV and gender-based violence, and their interlinkages, is being translated into action on the ground in fragile settings. These issues are explored through the lens of training of peace support operatio...ns deploying African troops across Africa and beyond.
more
After Workplace exposures and Sexual Assault
| DIRECTORATE: PRIMARY HEALTH CARE SERVICES
| DIVISION: PUBLIC AND ENVIRONMENTAL HEALTH
| SUB-DIVISION: OCCUPATIONAL HEALTH SERVICES
The COVID-19 pandemic arrived in an evolving epidemiological context where some countries are experiencing a progressive decrease in HIV positivity in their testing programme as they are moving closer to the first 95 target. Distinguishing changes in HIV testing services due to the COVID-19 pandemic... from those resulting from evolving HIV testing strategies is crucial for adapting services and helping countries define their strategic mix of testing options moving forward. There is a need to focus, prioritize and plan for strategic efforts to prevent going further off the track toward achieving global targets and goals.
To support these efforts, WHO in partnership with ministries of health conducted an in-depth analysis of HIV testing services and antiretroviral therapy (ART) initiation prior to and during reported COVID-19 disruptions. Additional publicly available Global Fund and PEPFAR data was also reviewed and analysed. This analysis, and coordination with ministries of health, identified key service delivery adaptations utilized during COVID-19-related disruptions and formed the basis of this strategic guide.
This document focuses on current country needs, as well as plans for prioritization and potential surge support needs in the event of future disruptions. Although the data and implications are specific to sub-Saharan Africa, key principles and lessons can be applied elsewhere.
more
Version dated April 1st, 2020.
The flow of migrants and refugees from Venezuela constitutes the largest mobilization of people in the history of Latin America. By March 2020, more than 4.9 million Venezuelans have left their country and from these, more than 4.1 million have been mobilized to count...ries in Latin America and the Caribbean. The motives for this mobilization are diverse, but those related to health care issues stand out, among which is the condition of living with HIV/AIDS. In the situation of demand for medical care that COVID-19 has generated, it is much more difficult to receive attention for people who are not included in the health systems of countries that are recipient due to the limitations that their migratory status may impose.
more
DHS Working Papers No. 101
Women’s empowerment, HIV testing, birth in past five years, Tanzania
Overcoming barriers in low- and middle-income countries
For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the various dimensions of access to HCV diagnostics and pha...rmaceutical products, including product pricing, the regulatory environment and patent status, which together shape the national hepatitis response in different settings. It highlights key areas for action by ministries of health and other government decision-makers, pharmaceutical manufacturers and technical partners.
more